Early Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function

Abby F. Fleisch, Sheryl L. Rifas-Shiman, Ana M. Mora, Antonia M. Calafat, Xiaoyun Ye, Heike Luttmann-Gibson, Matthew W. Gillman, Emily Oken, and Sharon K. Sagiv

National Institute of
Environmental Health Sciences

Early Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function

Abby F. Fleisch,[1] Sheryl L. Rifas-Shiman,[2] Ana M. Mora,[3,4] Antonia M. Calafat,[5] Xiaoyun Ye,[5] Heike Luttmann-Gibson,[6] Matthew W. Gillman,[2,7] Emily Oken,[2,7] and Sharon K. Sagiv[8]

[1]Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA

[2]Obesity Prevention Program, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

[3]Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA

[4]Central American Institute for Studies on Toxic Substances (IRET), Universidad Nacional, Heredia, Costa Rica

[5]Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

[6]Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA

[7]Department of Nutrition, Harvard School of Public Health, Boston, MA, USA

[8]Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA

Corresponding author:

Abby F. Fleisch, MD, MPH

Endocrinology Division, Boston Children's Hospital

300 Longwood Ave, Boston, MA 02115

abby.fleisch@childrens.harvard.edu; Phone: 617-355-7476; FAX: 617-730-0194

Running title: PFASs and Childhood Metabolic Function

Competing Financial Interests: MWG receives royalties from Maternal Obesity (Cambridge University Press, 2012). The other authors declare they have no actual or potential competing financial interests.

ABSTRACT

Background: Perfluoroalkyl substances (PFASs) are synthetic chemicals that may persist in the environment and in humans. There is a possible association between early life PFAS exposure and metabolic dysfunction in later life, but data are limited.

Methods: We studied 665 mother/child pairs in Project Viva, a Boston-area cohort recruited 1999-2002. We quantified concentrations of PFASs [perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), perfluorohexane sulfonate (PFHxS), and perfluorodecanoate (PFDeA)] in maternal plasma collected at the first prenatal visit (median 9.6 weeks gestation) and in child plasma from the mid-childhood research visit (median 7.7 years). We assessed leptin, adiponectin, and homeostatic model of insulin resistance (HOMA-IR) in mid-childhood. We fit covariate-adjusted linear regression models and conducted stratified analyses by child sex.

Results: Children with higher PFAS concentrations had lower HOMA-IR [e.g., -10.1% (95% CI: -17.3, -2.3) per interquartile range (IQR) increment in PFOA]. This inverse association between child PFAS and HOMA-IR was more pronounced in females [e.g., PFOA: -15.6% (95% CI: -25.4, -4.6) vs. -6.1% (95% CI: -16.2, 5.2) for males]. Child PFAS plasma concentrations were not associated with leptin or adiponectin. Prenatal PFAS plasma concentrations were not associated with leptin, adiponectin, or HOMA-IR in offspring.

Conclusions: We found no evidence for an adverse effect of early life PFAS exposure on metabolic function in mid-childhood. In fact, children with higher PFAS concentrations had lower insulin resistance.

INTRODUCTION

Perfluoroalkyl substances (PFASs) are synthetically produced compounds used as additives in clothing, furniture, carpets, and cookware to make the items non-stick and stain repellant (Lindstrom et al. 2011). Long-chain PFASs persist in the environment and in humans with a half-life of 3-5 years (Olsen et al. 2007). Also, several PFASs are ubiquitous and detectable in varying concentrations in almost all US children and adults (Calafat et al. 2007; Centers for Disease Control and Prevention 2015)].

PFASs have structural homology with fatty acids and may have endocrine disrupting properties. A growing body of literature suggests that PFAS exposure may contribute to metabolic dysfunction (Audouze et al. 2013; US Environmental Protection Agency 2013) through upregulation of fatty acid oxidation pathways (Guruge et al. 2006; Hu et al. 2005) and concomitantly increased oxidative stress (Karpe et al. 2011). However, PFASs also function as peroxisome proliferator-activated receptor (PPAR) agonists (Vanden Heuvel et al. 2006), which would be expected to improve, rather than exacerbate, insulin resistance.

The epidemiologic literature is in line with these conflicting mechanisms of action. Some (Lin et al. 2009; Lind et al. 2014; Timmermann et al. 2014) but not all (Fisher et al. 2013; MacNeil et al. 2009; Nelson et al. 2010) cross-sectional studies have linked PFAS burden with insulin resistance in adults and children. PFASs cross the placenta (Inoue et al. 2004), and in rodent models (Hines et al. 2009; Lv et al. 2013) and one prospective, population-based cohort study (Halldorsson et al. 2012), prenatally exposed offspring had greater metabolic dysfunction in adulthood. Thus, the relationship between PFASs and metabolic risk remains unclear.

In the present analysis, we evaluated the extent to which PFAS concentrations in prenatal and mid-childhood plasma were associated with biochemical markers of metabolic function in

children from a Boston-area birth cohort. Based on the existing literature linking prenatal PFAS

exposure with adverse metabolic profiles, we hypothesized that higher prenatal and mid-

childhood plasma PFAS concentrations would be associated with metabolic dysfunction, as

manifest by higher leptin, lower adiponectin, and higher HOMA-IR, in children.

METHODS
Study population and design

Pregnant women were recruited to Project Viva, a prospective cohort study of prenatal

exposures and offspring health, from 1999 to 2002 during their first prenatal visit (median 10

weeks gestation) at Atrius Harvard Vanguard Medical Associates, a multi-specialty group

practice in Eastern Massachusetts (Oken et al. 2015). Of 2,128 live singleton offspring, 1,116

(52.4%) children attended a mid-childhood follow-up visit (median age 7.7 years), and 667

(31.3%) had a blood draw during that visit with measurement of at least one metabolic

biomarker. Of these 667 children, 665 (99.7%) had PFAS measurements (536 with PFASs

measured in 1999-2002 maternal plasma and 643 with PFASs measured in 2007-2010 child

plasma) (see Supplemental Material, Figure S1). Mothers of children included in these analyses

(n=665) versus those excluded (n=1,463) were more likely to be multiparous, have lower plasma

PFAS concentrations, and were more likely to live in a census tract with lower median household

income and higher percent below poverty. Their children were more likely to be black or other

race/ethnicity (see Supplemental Material, Table S1).

We obtained written informed consent from mothers at each study visit and child verbal

assent at the mid-childhood visit. Institutional Review Boards of participating institutions

approved the study. The involvement of the Centers for Disease Control and Prevention (CDC)

did not constitute engagement in human subject research.

Exposure and outcome measurements

We measured concentrations of perfluorooctanoate (PFOA), perfluorooctane sulfonate

(PFOS), perfluorononanoate (PFNA), perfluorohexane sulfonate (PFHxS), and

perfluorodecanoate (PFDeA) in plasma collected from mothers in early pregnancy [median

(IQR) 9.6 (2.1) weeks gestation] and children in mid-childhood [median (IQR) 7.7 (1.0) years of

age], as previously described (Sagiv et al. 2015). Staff at the Division of Laboratory Sciences at

the CDC (Atlanta, GA) quantified PFASs using on-line solid-phase extraction coupled to isotope

dilution high performance liquid chromatography mass spectrometry. We measured total

concentrations of each PFAS in prenatal plasma in 2013. Subsequently, studies linked specific

PFAS isomers to health outcomes (Jiang et al. 2014; Yu et al. 2015). Thus, when we measured

PFAS concentrations in mid-childhood plasma in 2015, we separately measured linear and

branched isomers of PFOA [n-PFOA and the sum of perfluoromethylheptanoic and

perfluorodimethylhexanoic acids (Sb-PFOA)] and PFOS [n-PFOS, sum of

perfluoromethylheptane sulfonates (Sm-PFOS), and sum of perfluorodimethylhexane sulfonates

(Sm2-PFOS)] which we summed to obtain total PFOA and PFOS concentrations. The limit of

detection (LOD) was 0.1 ng/mL for all PFASs with the exception of PFOS concentration in

prenatal plasma (LOD 0.2 ng/mL). We replaced values below the LOD with the LOD/$\sqrt{2}$.

We assessed metabolic function in mid-childhood through serum concentrations of leptin

(marker of adiposity) and adiponectin (increases insulin sensitivity and decreases body weight)

(Tilg and Moschen 2006) which we measured by radioimmunoassay (Linco Research, St.

Charles, MO). We measured fasting insulin with an electrochemiluminescence immunoassay

(Roche Diagnostics, Indianapolis, IN) and fasting glucose enzymatically. We estimated insulin

resistance by calculating the homeostasis model assessment for insulin resistance (HOMA-IR) as

[fasting glucose (mg/dL) x fasting insulin (mU/L))/405].

Covariates

We collected data on maternal age, parity, smoking habits, education, partner education,

household income, and marital status using questionnaires at study enrollment. We also assessed

maternal glomerular filtration rate (GFR) and plasma volume expansion which increase during

pregnancy and are associated with lower PFAS plasma concentrations. To calculate GFR

(mL/min/1.73 m^2), we measured creatinine in the same prenatal blood samples used for

quantification of PFASs and used the Cockroft-Gault formula [GFR-CG = (140-age) x weight

(kg) x 1.04/serum creatinine (μmol/L)] (Cockcroft and Gault 1976). To assess maternal plasma

volume expansion, we (1) recorded the week of gestation during which the prenatal plasma

sample was obtained, and (2) measured plasma albumin in the same prenatal blood samples used

for PFAS quantification. Albumin, in addition to being an indicator for plasma volume

expansion during pregnancy, is also a major PFAS binding protein (D'Eon J et al. 2010), and can

be modeled in the same way as lipids in analyses of lipophilic compounds, such as

organochlorines (Gaskins and Schisterman 2009).

We abstracted infant sex and date of delivery from medical records. We collected data on

child race/ethnicity, breastfeeding duration, fast food intake, soda intake, physical activity,

screen time, passive smoke exposure, and household income using questionnaires during

childhood. We obtained median annual household income and percent of households below the

poverty threshold for the mother's residential census tract at the time of enrollment and in mid-childhood from 2000 US Census data (United States Census Bureau 2000).

Statistical analyses

In linear regression analyses, we examined associations of prenatal and mid-childhood PFAS plasma concentrations with leptin, adiponectin, and HOMA-IR in mid-childhood. We *a priori* decided to only consider PFASs with greater than 65% of detectable values, which included each PFAS (PFOA, PFOS, PFNA, PFHxS, and PFDeA) at each time point (prenatal and childhood), with the exception of prenatal plasma PFDeA (43.5% detectable values).

We ln=transformed serum concentrations of leptin, adiponectin, HOMA-IR to meet model assumptions. For ease of interpretation, we exponentiated regression coefficients and reported results as a percent change [% change = (exp(beta) - 1)*100].

We expressed continuous associations per interquartile range (IQR) increment in exposure. To evaluate nonlinearity and assess outlier influence, we modeled PFAS concentrations in quartiles and fit penalized spline generalized additive models.

We accounted for covariates potentially associated with PFAS plasma concentration (Sagiv et al. 2015) and/or metabolic function (Kimbro et al. 2007; Perng et al. 2014) in all of our final models. These covariates included maternal age at enrollment (continuous), maternal education (with or without college degree), child age at mid-childhood visit (continuous), child sex (dichotomous), child race/ethnicity (white, black, Asian, Hispanic, other), census tract median household income (continuous), and census tract percent below poverty (continuous). In analyses of prenatal PFASs, we additionally accounted for parity (nulliparous or multiparous), maternal smoking habits (smoked during pregnancy, formerly smoked, never smoked), and week

of gestation of PFAS measurement, as these covariates are potentially related to prenatal but not

mid-childhood PFAS plasma concentrations. In all analyses, we substituted maternal

race/ethnicity for child race/ethnicity for the 10% of participants missing data on this covariate,

which resulted in >99% of participants having race/ethnicity data.

We considered but did not include several variables in our final models that did not

confound the exposure-outcome relationship (i.e., the estimate for the primary exposure changed

by < 10%) or did not importantly change the results. These variables included maternal

breastfeeding duration, marital status, and serum albumin and GFR (in analyses of prenatal

PFASs), household income, partner education, and child fast food intake, soda intake, physical

activity, screen time, and passive smoke exposure (in analyses of child PFASs). We performed

complete case analyses excluding those with missing covariates, as complete covariate

information was available for 98% of participants with available exposure/outcome data.

Because prior studies have shown more pronounced associations between early life PFAS

exposure and insulin resistance in females (Halldorsson et al. 2012), we assessed for effect

modification by child sex, via an interaction term and stratification.

To further investigate the inverse association between child PFAS plasma concentrations

and HOMA-IR, we included all PFASs (PFOA, PFOS, PFNA, PFHxS, and PFDeA) in the same

covariate-adjusted model. Because insulin resistance increases during puberty (Vryonidou et al.

2015), we restricted to prepubertal participants (70% of full cohort) which allowed us to evaluate

whether a PFAS-delayed puberty association (Lopez-Espinosa et al. 2011) was driving the

inverse association between child PFAS plasma concentration and HOMA-IR. We considered

participants to be prepubertal if their parents reported absence of body hair growth (boys and

girls), voice deepening (boys), facial hair growth (boys), and breast development (girls) [i.e., a subset of validated pubertal development scale questions (Carskadon and Acebo 1993)].

In a final sensitivity analysis, we examined the extent to which different isomers of PFAS were associated with childhood metabolic profile. We considered all isomer concentrations with greater than 65% detectable values (n-PFOA, n-PFOS, Sm-PFOS; see Supplemental Material, Table S2).

For penalized spline generalized additive models, we used R Version 3.0.0 (R Foundation for Statistical Computing), and for all other analyses, we used SAS version 9.3 (SAS Institute).

RESULTS

Population characteristics

Median (IQR) maternal age at the time of prenatal enrollment was 32.5 (7.1) years; 42% of mothers were nulliparous and 64% were college graduates. Fifty-nine percent of children were white. At the mid-childhood follow-up visit [median (IQR) age of 7.7 (1.0) years], median (IQR) leptin was 3.3 (3.9) ng/mL, adiponectin 14.0 (9.7) µg/mL, and HOMA-IR 1.5 (1.3) (Table 1).

Prenatal PFAS plasma concentrations in our cohort were typical for US women during peak production, 1999-2000, and childhood PFAS plasma concentrations were similar to concentrations reported in US children from 2007-2008 (Centers for Disease Control and Prevention 2015) (Table 2). At both time points, highest concentrations were of PFOS although mid-childhood concentrations were substantially lower than prenatal concentrations [PFOS median (25th, 75th percentile) was 24.4 (17.9, 33.9) ng/mL in prenatal plasma and 6.2 (4.2, 9.7) ng/mL in childhood plasma]. Spearman correlations of PFAS concentrations in prenatal plasma

were 0.24-0.72 and in mid-childhood plasma were 0.13-0.78. Correlations of the same PFASs

measured in prenatal versus mid-childhood plasma were 0.08-0.40 (Table 2).

Mothers with higher PFOA concentrations during pregnancy were more likely to be

younger, nulliparous, less educated, non-smokers, to have had blood collection earlier in

pregnancy, and to live in a census tract with lower percent below poverty, and their children

were more likely to be white (Table 1). These associations were not consistent across all PFASs,

with a markedly different pattern of associations for PFNA in our cohort, as described previously

(Sagiv et al. 2015). Children with higher PFOA concentrations in mid-childhood were more

likely to live in a census tract with higher median household income and lower percent below

poverty and to be white, younger and to have lower leptin, and lower HOMA-IR (see

Supplemental Material, Table S3). Mothers of children with higher PFOA concentrations were

more likely to be older and college graduates.

Prenatal PFAS concentrations and mid-childhood metabolic profile

Prenatal PFAS plasma concentrations were not associated with leptin, adiponectin, or

HOMA-IR in mid-childhood in unadjusted (data not shown) or covariate-adjusted (Table 3)

analyses. For example, adjusted effect estimates were null for the associations of maternal PFOA

concentrations with mid-childhood leptin (1.7% per IQR increment, 95% CI: -7.6, 12.0),

adiponectin (1.2%, 95% CI: -7.2, 5.2), and HOMA-IR (-0.7%, 95% CI: -9.8, 9.4) (Table 3).

Mid-childhood PFAS concentrations and metabolic profile

Mid-childhood PFAS concentrations were not associated with leptin or adiponectin

measured at the same time in unadjusted (data not shown) or adjusted (Table 4) analyses, with

the exception of consistently lower leptin in children in higher quartiles (Q2-4) of PFOA plasma concentrations [versus the lowest quartile (Q1)].

Children with higher PFAS concentrations had lower HOMA-IR with weaker associations in covariate-adjusted [e.g., 10.1% lower HOMA-IR (95% CI: -17.3, -2.3) per IQR increment in PFOA; Table 4] versus unadjusted [e.g., 14.7% lower (95% CI -21.1, -7.8) per IQR increment in PFOA; data not shown] models. Strongest covariate-adjustedassociations were with PFDeA [14.7% lower HOMA-IR (95% CI: -22.1, -6.5) per IQR increment] with weaker, imprecise effect estimates for PFHxS and PFNA (Table 4). Notably, HOMA-IR was monotonically lower across quartiles of PFOS and PFHxS concentrations, consistently lower in Q3 and Q4 versus Q1 of PFOA and PFDeA concentrations, and consistently lower in Q2-4 versus Q1 of PFNA concentration.

Covariate-adjusted penalized spline models of mid-childhood PFAS plasma concentrations and HOMA-IR were consistent with the quartile results. PFOS and PFHxS had an inverse dose-response association with HOMA-IR, and higher PFOA, PFNA, and PFDeA concentrations were also associated with lower HOMA-IR with possible thresholds of association. In all cases, effect estimates were imprecise in the higher PFAS concentration range where there were fewer values (see Supplemental Material, Figure S2).

Effect modification and stratification by sex

Child sex modified the associations between prenatal PFHxS concentration and HOMA-IR [p=0.04; inverse association for boys and null for girls (data not shown)] and childhood PFOS concentration and HOMA-IR [p=0.03; inverse association for girls and null for boys (see Supplemental Material, Table S4)]. Additionally, we observed sex-specific patterns in the

associations between childhood PFAS concentrations and HOMA-IR in stratified analyses, even in cases where the interaction term was not significant. Specifically, childhood PFOA, PFOS, and PFDeA concentrations were inversely associated with HOMA-IR in girls with null associations in boys (see Supplemental Material, Table S4).

Sensitivity analyses

When we included all childhood PFAS plasma concentrations in the same covariate-adjusted model predicting HOMA-IR, PFDeA was the only PFAS significantly associated with HOMA-IR (data not shown). HOMA-IR was 14.5% (95% CI: -24.7, -2.9) lower per IQR increment in PFDeA.

When we examined the association between childhood PFAS plasma concentrations and HOMA-IR among only prepubertal participants [covariate-adjusted n=386; median age (IQR) = 7.6 (0.8) years], adjusted effect estimates were similar to those for the full cohort. For example, among prepubertal participants HOMA-IR was 9.3% (95% CI: -17.4, -0.5) lower per IQR increment in PFOA, 9.1% (95% CI: -16.0, -1.8) lower per IQR increment in PFOS, and 12.4% (95% CI: -20.8, -3.2) lower per IQR increment in PFDeA.

Linear and branched isomers of PFOA and PFOS measured in mid-childhood had similar patterns of association with mid-childhood metabolic profile as total concentrations of PFOA and PFOS [i.e., no association with leptin or adiponectin (data not shown) and inverse association with HOMA-IR]. HOMA-IR was 11.0% (95% CI: -18.3, -3.0) lower per IQR increment in n-PFOA, 9.5% (95% CI: -15.8, -2.7) lower per IQR increment in n-PFOS, and 12.3% (95% CI: -19.1, -5.0) lower per IQR increment in Sm-PFOS.

DISCUSSION

In a large, prospective Boston-area cohort, we found no evidence for an adverse association of prenatal or mid-childhood PFAS exposure with metabolic profile in children. Prenatal PFAS concentrations in early pregnancy were not associated with dysmetabolism in offspring in mid-childhood, and childhood PFAS concentrations were not contemporaneously associated with leptin or adiponectin. In fact, contrary to our *a priori* hypothesis, children with higher plasma concentrations of PFASs had lower HOMA-IR (i.e., less insulin resistance), with the strongest associations for PFDeA and in girls.

Our findings are biologically plausible given that PFASs may have a combination of detrimental and beneficial effects on metabolic status. For instance, PFASs are structurally similar to fatty acids, and *in vitro*, PFASs increase the expression of genes involved in fatty acid oxidation (Guruge et al. 2006; Hu et al. 2005). Upregulation of fatty acid oxidation has been postulated to increase oxidative stress which, in turn, exacerbates insulin resistance (Karpe et al. 2011). On the other hand, but also based on their structural homology to fatty acids, PFASs activate nuclear peroxisome proliferator-activated receptor (PPAR) gamma (γ) (Vanden Heuvel et al. 2006). Through PPAR-γ activation, PFAS exposure could improve insulin sensitivity by triggering the expression of genes that stimulate free fatty acid storage and thereby necessitate the use of glucose rather than fatty acids as a fuel substrate (Janani and Ranjitha Kumari 2015). Thiazolidinediones, PPAR-γ agonists used to treat type 2 diabetes, have been shown to lower serum insulin even in normal weight individuals without diabetes (Yu et al. 2002). Also, recent cohorts have shown a protective association between PFAS exposure and neurocognitive/behavioral dysfunction (Power et al. 2013; Stein et al. 2013), hypothesized to

result from PPAR-γ activation, although other studies [e.g.,(Hoffman et al. 2010)] have shown

null or direct associations.

As expected based on these contradictory mechanistic underpinnings, prior epidemiologic

analyses have not shown a consistent association between PFAS exposure and insulin resistance

in adult cohorts. In studies of the Canadian Health Measures Survey (Fisher et al. 2013) and US

National Health and Nutrition Examination Survey (Nelson et al. 2010), PFAS plasma

concentrations were not associated with HOMA-IR. Similarly, in a cohort of ~55,000 US adults

with PFOA concentrations above background due to contaminated drinking water, there was no

association between PFOA concentrations and diabetes, although when restricted to ~14,000

individuals with unchanged residential water district for > 20 years, higher PFOA was associated

with decreased risk of diabetes (MacNeil et al. 2009). In two additional adolescent/adult cohorts

(Lin et al. 2009; Lind et al. 2014), there were associations between some but not all PFASs and

some but not all metabolic endpoints [e.g., association between PFNA, but not 6 other measured

PFASs, and diabetes risk, but not HOMA-IR (Lind et al. 2014)].

Our study adds to the existing literature by examining PFAS exposure during fetal

development and in childhood, life stages during which individuals are potentially more

vulnerable to environmental insults (Symonds et al. 2009). While our finding of no adverse

effect of PFASs on metabolic status is in line with the cross-sectional adult studies, it is less

consistent with the one prior prospective cohort study of prenatal PFAS exposure and offspring

metabolic health in which higher maternal PFOA (but not PFOS, PFNA, or perfluorooctane

sulfonamide) concentrations were associated with higher HOMA-IR, higher leptin, and lower

adiponectin in female, but not male, offspring at 20 years of age (Halldorsson et al. 2012). In our

cohort, we also found stronger associations in females, but associations were inverse and for

childhood rather than prenatal PFAS concentrations. Individuals who are predisposed to develop

insulin resistance due to male sex (Friend et al. 2013) may do so regardless of any potential

effect of PFASs, although these sex-stratified findings require replication.

Our findings are also partly inconsistent with a cross-sectional study of 8-10 year old

Danish children in which PFOA and PFOS plasma concentrations were associated with higher

HOMA-IR, but not leptin or adiponectin, in overweight, but not normal weight children

(Timmermann et al. 2014). In the present study, we opted not to assess for effect modification by

child weight because of the possibility that weight is on the causal pathway and potential for

collider bias (Cole et al. 2010).

We recognize that our finding of an inverse association between PFAS concentrations

and insulin resistance in childhood could be due to chance or residual confounding. We

performed a large number of analyses, and multiple testing could have led to statistically

significant associations by chance, although consistent patterns in our results suggests against

this possibility. Additionally, residual negative confounding could have occurred by

socioeconomic status (SES) which is directly associated with PFAS concentrations (see

Supplemental Material, Table S3) and inversely associated with insulin resistance in Project

Viva (data not shown). However, we accounted for several individual (race/ethnicity, education)

and census tract (median household income, percent below poverty) markers of SES in

covariate-adjusted analyses presented here, and we saw no attenuation of results when we

additionally controlled for individual-level household income or SES-related behavioral

determinants of metabolic health (fast food intake, soda intake, physical activity, and screen

time). We also considered the possibility that because insulin resistance increases during puberty

(Vryonidou et al. 2015), an association between PFAS concentrations and delayed puberty

16

(Lopez-Espinosa et al. 2011) could have driven the inverse association between childhood PFAS concentrations and HOMA-IR. However, when we restricted analyses to prepubertal children, effect estimates were similar to those obtained from the full cohort, suggesting against this possibility. Additional, well-controlled studies of early life PFAS exposure in post-pubertal children and adults will help to confirm the magnitude and directionality of the association with metabolic status.

In our cohort, PFDeA had a stronger inverse association with HOMA-IR than concentrations of the other PFASs, in both individual- and multi-pollutant models. However, our study was limited based on our inability to conduct analyses of prenatal PFDeA due to the large number of plasma samples with concentrations below the LOD. In addition, childhood PFDeA plasma concentration had relatively low variability. Few human health studies have evaluated PFDeA, and additional research would increase our understanding of the potential role of PFDeA on health outcomes. Also, in our study, plasma concentrations of several PFASs were non-monotonically associated with lower HOMA-IR. Attention to the pattern of PFAS associations with health outcomes in future studies would help to elucidate whether a threshold effect exists.

Generalizability is a limitation of Project Viva because our cohort is comprised of primarily white children of moderately high SES. Strengths of the study include use of a large, prospective cohort with multiple potential confounding variables, measurement of plasma concentrations of several PFASs at different time points, and biochemical measures of metabolic function in childhood.

In summary, we found no evidence for an adverse effect of early life PFAS exposure on metabolic function in mid-childhood. In our cohort, children with higher PFAS plasma concentrations had lower insulin resistance. Although this finding is biologically plausible, it is

17

in contrast to the existing limited literature on early life PFAS exposure and would benefit from

replication.

REFERENCES

Audouze K, Brunak S, Grandjean P. 2013. A computational approach to chemical etiologies of diabetes. Sci Rep 3: 2712.

Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. 2007. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol 41(7): 2237-2242.

Carskadon MA, Acebo C. 1993. A self-administered rating scale for pubertal development. J Adolesc Health 14(3): 190-195.

Centers for Disease Control and Prevention. 2015. CDC Fourth National Report on Human Exposure to Environmental Chemicals. Updated Tables, February 2015. Available: http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.pdf. [Accessed 29 January 2016].

Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16(1): 31-41.

Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. 2010. Illustrating bias due to conditioning on a collider. Int J Epidemiol 39(2): 417-420.

D'Eon J C, Simpson AJ, Kumar R, Baer AJ, Mabury SA. 2010. Determining the molecular interactions of perfluorinated carboxylic acids with human sera and isolated human serum albumin using nuclear magnetic resonance spectroscopy. Environ Toxicol Chem 29(8): 1678-1688.

Fisher M, Arbuckle TE, Wade M, Haines DA. 2013. Do perfluoroalkyl substances affect metabolic function and plasma lipids?--Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. Environ Res 121: 95-103.

Friend A, Craig L, Turner S. 2013. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab Syndr Relat Disord 11(2): 71-80.

Gaskins AJ, Schisterman EF. 2009. The effect of lipid adjustment on the analysis of environmental contaminants and the outcome of human health risks. Methods Mol Biol 580: 371-381.

Guruge KS, Yeung LW, Yamanaka N, Miyazaki S, Lam PK, Giesy JP, et al. 2006. Gene expression profiles in rat liver treated with perfluorooctanoic acid (PFOA). Toxicol Sci 89(1): 93-107.

Halldorsson TI, Rytter D, Haug LS, Bech BH, Danielsen I, Becher G, et al. 2012. Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. Environ Health Perspect 120(5): 668-673.

Hines EP, White SS, Stanko JP, Gibbs-Flournoy EA, Lau C, Fenton SE. 2009. Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. Mol Cell Endocrinol 304(1-2): 97-105.

Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. 2010. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect 118(12): 1762-1767.

Hu W, Jones PD, Celius T, Giesy JP. 2005. Identification of genes responsive to PFOS using gene expression profiling. Environ Toxicol Pharmacol 19(1): 57-70.

Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 112(11): 1204-1207.

Janani C, Ranjitha Kumari BD. 2015. PPAR gamma gene--a review. Diabetes Metab Syndr 9(1): 46-50.

Jiang W, Zhang Y, Zhu L, Deng J. 2014. Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women. Environ Int 64: 40-47.

Karpe F, Dickmann JR, Frayn KN. 2011. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60(10): 2441-2449.

Kimbro RT, Brooks-Gunn J, McLanahan S. 2007. Racial and ethnic differentials in overweight and obesity among 3-year-old children. Am J Public Health 97(2): 298-305.

Lin CY, Chen PC, Lin YC, Lin LY. 2009. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care 32(4): 702-707.

Lind L, Zethelius B, Salihovic S, van Bavel B, Lind PM. 2014. Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly. Diabetologia 57(3): 473-479.

Lindstrom AB, Strynar MJ, Libelo EL. 2011. Polyfluorinated compounds: past, present, and future. Environ Sci Technol 45(19): 7954-7961.

Lopez-Espinosa MJ, Fletcher T, Armstrong B, Genser B, Dhatariya K, Mondal D, et al. 2011. Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with age of puberty among children living near a chemical plant. Environ Sci Technol 45(19): 8160-8166.

Lv Z, Li G, Li Y, Ying C, Chen J, Chen T, et al. 2013. Glucose and lipid homeostasis in adult rat is impaired by early-life exposure to perfluorooctane sulfonate. Environ Toxicol 28(9): 532-542.

MacNeil J, Steenland NK, Shankar A, Ducatman A. 2009. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). Environ Res 109(8): 997-1003.

Nelson JW, Hatch EE, Webster TF. 2010. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 118(2): 197-202.

Oken E, Baccarelli AA, Gold DR, Kleinman KP, Litonjua AA, De Meo D, et al. 2015. Cohort profile: project viva. Int J Epidemiol 44(1): 37-48.

Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115(9): 1298-1305.

Perng W, Gillman MW, Mantzoros CS, Oken E. 2014. A prospective study of maternal prenatal weight and offspring cardiometabolic health in midchildhood. Ann Epidemiol 24(11): 793-800 e791.

Power MC, Webster TF, Baccarelli AA, Weisskopf MG. 2013. Cross-sectional association between polyfluoroalkyl chemicals and cognitive limitation in the National Health and Nutrition Examination Survey. Neuroepidemiology 40(2): 125-132.

Sagiv SK, Rifas-Shiman SL, Webster TF, Mora AM, Harris MH, Calafat AM, et al. 2015. Sociodemographic and Perinatal Predictors of Early Pregnancy Per- and Polyfluoroalkyl Substance (PFAS) Concentrations. Environ Sci Technol 49(19): 11849-11858.

Stein CR, Savitz DA, Bellinger DC. 2013. Perfluorooctanoate and neuropsychological outcomes in children. Epidemiology 24(4): 590-599.

Symonds ME, Sebert SP, Hyatt MA, Budge H. 2009. Nutritional programming of the metabolic syndrome. Nat Rev Endocrinol 5(11): 604-610.

Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10): 772-783.

Timmermann CA, Rossing LI, Grontved A, Ried-Larsen M, Dalgard C, Andersen LB, et al. 2014. Adiposity and glycemic control in children exposed to perfluorinated compounds. J Clin Endocrinol Metab 99(4): E608-614.

United States Census Bureau. 2000. US Census 2000: Summary File 3. Available: http://www.census.gov/census2000/sumfile3.html [Accessed 18 May 2015].

US Environmental Protection Agency. 2013. America's Children and the Environment: Third Edition. Available: http://www.epa.gov/ace/pdfs/ACE3_2013.pdf. [Accessed 27 August 2015].

Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci 92(2): 476-489.

Vryonidou A, Paschou SA, Muscogiuri G, Orio F, Goulis DG. 2015. Mechanisms in Endocrinology: Metabolic syndrome through the female life cycle. Eur J Endocrinol 173(5): R153-163.

Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. 2002. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51(10): 2968-2974.

Yu N, Wang X, Zhang B, Yang J, Li M, Li J, et al. 2015. Distribution of perfluorooctane sulfonate isomers and predicted risk of thyroid hormonal perturbation in drinking water. Water Res 76: 171-180.

Table 1. Participant characteristics overall (n=665 in analytic dataset)[a] and by prenatal PFOA plasma concentration (n=536 participants in analytic dataset with measurement of prenatal PFOA).

	Overall n= 665	Quartiles[b] of prenatal PFOA			
		Q1 (lowest) n=151	Q2 n=147	Q3 n=123	Q4 (highest) n=115
	Median (IQR) or %	Median (IQR) or %			
Maternal characteristics					
Age at enrollment (years)	32.5 (7.1)	33.9 (6.3)	31.9 (6.6)	32.0 (7.7)	31.2 (7.7)
Prepregnancy BMI (kg/m^2)	23.7 (5.9)	23.6 (6.4)	23.8 (5.3)	23.4 (5.7)	24.1 (5.9)
Nulliparous (%)	42	23	41	54	62
College graduate (%)	64	71	68	65	59
Smoking habits (%)					
Never	69	74	70	66	65
Former	19	18	16	23	23
During pregnancy	11	8	14	11	12
Time of prenatal PFAS measurement (weeks gestation)[c]	9.6 (2.1)	9.9 (2.1)	9.7 (2.6)	9.4 (2.1)	9.4 (1.9)
Albumin (g/dL)	8.3 (2.3)	8.1 (2.2)	7.9 (2.2)	8.3 (2.0)	8.8 (2.4)
GFR (mL/min/1.73 m^2)	101.9 (46.0)	102.1 (44.8)	107.9 (56.2)	97.3 (41.5)	99.9 (44.8)
Partner/ Household/Neighborhood characteristics at enrollment					
Individual-level household income greater than $70,000 (%)	61	54	64	66	66
Median household income in census tract ($)	51,798 (28,921)	51,816 (33,732)	51,772 (28,322)	55,625 (27,201)	51,681 (22,681)
Percent below poverty in census tract	7.4 (11.8)	9.0 (14.1)	7.1 (10.8)	6.6 (8.5)	6.6 (8.7)

Child characteristics

Female (%)	47	50	42	41	52
Race/ethnicity (%)[d]					
White	59	55	63	67	64
Black	22	25	17	16	17
Hispanic	5	5	5	6	6
Asian	2	1	3	2	0
Other	11	13	12	9	12
Age at mid-childhood visit (years)	7.7 (1.0)	7.7 (1.1)	7.7 (1.1)	7.8 (0.9)	7.8 (1.0)

Mid-childhood cardiometabolic

Leptin (ng/mL)	3.3 (3.9)	3.2 (3.4)	3.3 (4.8)	3.5 (3.0)	3.1 (5.0)
Adiponectin (μg/mL)	14.0 (9.7)	15.0 (11.0)	14.0 (9.5)	13.9 (9.5)	13.8 (7.9)
HOMA-IR	1.5 (1.3)	1.5 (1.1)	1.6 (1.7)	1.5 (1.3)	1.5 (1.5)

Abbreviations: BMI: body mass index; GFR: glomerular filtration rate; HOMA-IR: homeostatic model assessment of insulin resistance; IQR: interquartile range; PFAS: perfluoroalkyl substances; PFOA: perfluorooctanoate; Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4

[a]Missing data for participants overall (n=665): 4 participants missing maternal prepregnancy BMI and education, 1 maternal smoking status, 160 albumin, 138 GFR, 67 individual-level household income, 8 census tract variables, 2 race/ethnicity, 6 age at mid-childhood visit, 52 leptin/adiponectin, 106 HOMA-IR

[b]PFOA quartile maximum and minimum values: 0.9-4.1 ng/mL for Q1, 4.2-5.8 ng/mL for Q2, 5.9-7.9 ng/mL for Q3, and 8.0-22.4 ng/mL for Q4

[c] Percent with prenatal PFAS measured in the second trimester: 11% for Q1, 13% for Q2, 9% for Q3, and 2% for Q4

[d]Maternal race/ethnicity was substituted in 10% of children whose race/ethnicity was missing.

Table 2. PFAS plasma concentration distributions and Spearman correlation coefficients for PFAS with greater than 65% of detectable values

	Prenatal (median 9.6 weeks gestation) PFAS plasma concentration (ng/mL)				Mid-childhood (median 7.7 years) PFAS plasma concentration (ng/mL)				
Exposure	PFOA	PFOS	PFNA	PFHxS	PFOA	PFOS	PFNA	PFHxS	PFDeA
Geometric mean (25th, 75th %ile)	5.3 (3.9, 7.6)	24.4 (17.9, 33.9)	0.6 (0.5, 0.9)	2.5 (1.6, 3.8)	4.2 (3.1, 6.0)	6.2 (4.2, 9.7)	1.7 (1.1, 2.3)	2.2 (1.2, 3.4)	0.3 (0.2, 0.5)
Minimum	0.9	4.6	<LOD (0.1)	<LOD (0.1)	<LOD (0.1)	<LOD (0.1)	<LOD (0.1)	<LOD (0.1)	<LOD (0.1)
Maximum	22.4	168.0	2.6	43.2	14.3	51.4	25.7	56.8	1.9
% below LOD	0	0	1.3	0.4	0.5	0.5	0.5	0.5	12
NHANES geometric mean	4.8[a]	28.0[a]	0.5[a]	1.8[a]	3.9[b]	11.3[b]	1.2[b]	2.4[b]	0.23[b]
	Spearman correlation coefficients								
Prenatal									
PFOA	1.00								
PFOS	0.72	1.00							
PFNA	0.56	0.67	1.00						
PFHxS	0.55	0.55	0.45	1.00					
Mid-childhood									
PFOA	0.15	0.10	0.08	0.18	1.00				
PFOS	0.09	0.12	0.11	0.14	0.78	1.00			
PFNA	0.11	0.10	0.08	0.07	0.43	0.34	1.00		
PFHxS	0.12	0.12	0.07	0.40	0.59	0.66	0.13	1.00	
PFDeA	0.10	0.13	0.11	0.08	0.69	0.59	0.55	0.34	1.00

Abbreviations: NHANES: US National Health and Nutrition Examination Survey; PFAS: perfluoroalkyl substances; PFOA: perfluorooctanoate; PFOS: perfluorooctane sulfonate; PFNA: perfluorononanoate; PFHxS: perfluorohexane sulfonate; PFDeA: perfluorodecanoate; LOD: limit of detection
[a]Women 1999-2000 (Calafat et al. 2007; Centers for Disease Control and Prevention 2015)
[b]12-19 year old children 2007-2008 (Calafat et al. 2007; Centers for Disease Control and Prevention 2015)

Table 3. Covariate-adjusted[a] associations of prenatal PFAS concentrations in maternal plasma in early pregnancy with cardiometabolic biomarkers in mid-childhood (median: 7.7 years of age).

	Leptin n=484	Adiponectin n=484	HOMA-IR n=441
PFOA			
IQR (3.8 ng/mL)	1.7 (-7.6, 12.0)	-1.2 (-7.2, 5.2)	-0.7 (-9.8, 9.4)
Q1 (0.9-4.1 ng/mL)	Reference	Reference	Reference
Q2 (4.2-5.8 ng/mL)	7.3 (-11.8, 30.6)	**-13.3 (-23.6, -1.5)**	8.0 (-11.3, 31.3)
Q3 (5.9-7.9 ng/mL)	4.6 (-15.6, 29.7)	-2.1 (-14.8, 12.4)	4.4 (-15.3, 28.8)
Q4 (8.0-22.4 ng/mL)	3.0 (-17.4, 28.5)	-2.4 (-15.4, 12.6)	3.0 (-17.2, 28.1)
PFOS			
IQR (16.0 ng/mL)	-0.3 (-7.7, 7.6)	1.1 (-3.8, 6.2)	-0.6 (-8.2, 7.6)
Q1 (4.6-18.8 ng/mL)	Reference	Reference	Reference
Q2 (18.9-25.5 ng/mL)	2.2 (-16.1, 24.5)	1.3 (-10.9, 15.2)	-12.2 (-27.7, 6.7)
Q3 (25.7-34.8 ng/mL)	5.1 (-15.0, 29.9)	0.8 (-12.2, 15.7)	-12.0 (-28.6, 8.5)
Q4 (34.9-168.0 ng/mL)	6.8 (-13.8, 32.3)	-2.2 (-14.9, 12.4)	1.6 (-17.9, 25.8)
PFNA			
IQR (0.4 ng/mL)	0.5 (-8.8, 10.8)	-5.5 (-11.3, 0.6)	1.4 (-8, 11.7)
Q1 [<LOD (0.1)-0.40 ng/mL]	Reference	Reference	Reference
Q2 (0.50-0.60 ng/mL)	21.6 (-0.9, 49.2)	0.6 (-11.9, 14.9)	7.8 (-11.8, 31.9)
Q3 (0.70-0.90 ng/mL)	18.6 (-4.2, 46.9)	-8.2 (-20.1, 5.5)	13.1 (-8.6, 39.8)
Q4 (1.0-2.6 ng/mL)	5.1 (-17.6, 34.1)	-13.0 (-25.7, 1.9)	2.9 (-19.2, 31.1)
PFHxS			
IQR (2.2 ng/mL)	-3.1 (-7.5, 1.5)	0.6 (-2.4, 3.6)	-2.0 (-5.9, 2.0)
Q1 [<LOD (0.1)-1.6 ng/mL]	Reference	Reference	Reference
Q2 (1.7-2.4 ng/mL)	13.5 (-7.3, 39)	-3.1 (-15.1, 10.6)	-6.7 (-23.7, 14.2)
Q3 (2.5-3.7 ng/mL)	13.8 (-7.6, 40.2)	-3.7 (-15.9, 10.3)	-13.5 (-29.6, 6.3)
Q4 (3.8-43.2 ng/mL)	2.8 (-16.2, 26)	-5.4 (-17.1, 8.1)	-17.1 (-32.3, 1.6)

Estimates are presented as percent change (95% confidence intervals) in outcome for (1) concentration quartiles 2-4 versus quartile 1 and (2) for each interquartile range increment in concentrations. Estimates with 95% confidence intervals that do not cross the null are bolded.

26

Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IQR: interquartile range; LOD: limit of detection; PFAS: perfluoroalkyl substances; PFOA: perfluorooctanoate; PFOS: perfluorooctane sulfonate; PFNA: perfluorononanoate; PFHxS: perfluorohexane sulfonate; Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4

[a]Model adjusted for characteristics of child (age, sex, race/ethnicity), mother (age, education, parity, smoking during pregnancy), neighborhood census tract at enrollment (median household income, percent below poverty), and pregnancy hemodynamics (time of blood draw in weeks gestation)

Table 4. Covariate-adjusted[a] associations of mid-childhood PFAS plasma concentrations with cardiometabolic biomarkers at the same time (median: 7.7 years of age).

	Leptin n=584	Adiponectin n=584	HOMA-IR n=541
PFOA			
IQR (2.9 ng/mL)	-5.0 (-12.9, 3.6)	1.0 (-4.9, 7.4)	**-10.1 (-17.3, -2.3)**
Q1 [<LOD (0.1)-3.0 ng/mL]	Reference	Reference	Reference
Q2 (3.1-4.3 ng/mL)	-17.2 (-31.6, 0.2)	**16.3 (1.8, 32.9)**	-14.9 (-29.4, 2.6)
Q3 (4.4-6.0 ng/mL)	**-23.3 (-37.0, -6.5)**	**22.7 (6.9, 40.8)**	**-27.3 (-40.0, -12.0)**
Q4 (6.1-14.3 ng/mL)	**-20.1 (-35.1, -1.6)**	9.7 (-5.1, 26.8)	**-25.3 (-38.7, -9.0)**
PFOS			
IQR (5.5 ng/mL)	-5.2 (-11.4, 1.4)	-0.5 (-5.1, 4.3)	**-10.1 (-16.4, -3.3)**
Q1 [<LOD (0.1)-4.2 ng/mL]	Reference	Reference	Reference
Q2 (4.2-6.2 ng/mL)	6.6 (-11.3, 28.1)	-1.3 (-13.3, 12.2)	3.4 (-13.6, 23.6)
Q3 (6.2-9.7 ng/mL)	-4.2 (-20.9, 16.1)	1.2 (-11.5, 15.8)	-12.9 (-27.6, 4.8)
Q4 (9.8-51.4 ng/mL)	-17.1 (-31.9, 0.8)	0.9 (-12, 15.8)	**-24.7 (-37.8, -8.8)**
PFNA			
IQR (1.2 ng/mL)	0.8 (-2.2, 4.0)	-2.1 (-4.2, 0.0)	-0.6 (-3.6, 2.6)
Q1 [<LOD (0.1)-1.0 ng/mL]	Reference	Reference	Reference
Q2 (1.1-1.5 ng/mL)	-13.9 (-28.1, 3.0)	-8.6 (-19.3, 3.5)	**-25.0 (-37.0, -10.7)**
Q3 (1.6-2.3 ng/mL)	-6.6 (-23.2, 13.5)	7.5 (-6.1, 23.1)	**-27.1 (-39.4, -12.1)**
Q4 (2.4-25.7 ng/mL)	-9.0 (-24.8, 10.1)	-9.1 (-20.4, 3.7)	**-25.6 (-38.0, -10.7)**
PFHxS			
IQR (2.2 ng/mL)	-0.3 (-2.6, 2.2)	0.3 (-1.4, 1.9)	-1.7 (-3.8, 0.5)
Q1 [<LOD (0.1)-1.1 ng/mL]	Reference	Reference	Reference
Q2 (1.2-1.9 ng/mL)	-4.3 (-20.3, 14.9)	-6.5 (-17.8, 6.2)	-5.1 (-20.9, 13.8)
Q3 (2.0-3.4 ng/mL)	-7.5 (-23.6, 11.9)	4.3 (-8.7, 19.1)	-6.7 (-22.7, 12.6)
Q4 (3.5-56.8 ng/mL)	**-19.4 (-33.7, -2.1)**	3.4 (-9.8, 18.5)	-16.8 (-31.4, 0.8)
PFDeA			
IQR (0.3 ng/mL)	-8.2 (-16.6, 0.9)	5.1 (-1.7, 12.3)	**-14.7 (-22.1, -6.5)**
Q1 [<LOD (0.1)-0.2 ng/mL]	Reference	Reference	Reference
Q2 (≥0.3-<0.4 ng/mL)	-9.3 (-24.4, 8.8)	6.1 (-6.5, 20.4)	-7.1 (-22.1, 10.6)

Q3 (≥0.4-<0.5 ng/mL)	-8.2 (-24.2, 11.0)	**18.0 (3.3, 34.7)**	**-31.3 (-42.8, -17.5)**
Q4 (0.5-1.9 ng/mL)	-10.9 (-25.7, 6.9)	9.0 (-4.0, 23.7)	**-21.5 (-34.0, -6.7)**

Estimates are presented as percent change (95% confidence intervals) in outcome for (1) concentration quartiles 2-4 versus quartile 1 and (2) for each interquartile range increment in concentration. Estimates with 95% confidence intervals that do not cross the null are bolded.

Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IQR: interquartile range; LOD: limit of detection; PFAS: perfluoroalkyl substances; PFOA: perfluorooctanoate; PFOS: perfluorooctane sulfonate; PFNA: perfluorononanoate; PFHxS: perfluorohexane sulfonate; PFDeA: perfluorodecanoate; Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4

[a] Model adjusted for characteristics of child (age, sex, race/ethnicity), mother (age, education), and neighborhood census tract at mid-childhood (median household income, percent below poverty)